Key Highlights

  • 2.5 USD is the per-share loss built into the consensus EPS estimate of -2.5 for Tevogen Inc. (NASDAQ:TVGN), due to report third-quarter 2026 results once trading ends on November 13, 2026.
  • 1.52 USD was the second-quarter 2026 per-share loss tied to a Deficit of USD 5,761,940, while the six-month deficit reached USD 11,208,195, or USD 3.16 per share, as shown in the quarterly filing.
  • 1.08 million USD was the cash on hand at June 30, 2026, compared with USD 552,372 at December 31, 2025, after USD 6.4 million was drawn from a Loan by a related party, leaving USD 11.0 million available.
  • 100.56 million USD is the Market Value in the screening snapshot, set against 6,511,540 shares outstanding on August 10, 2026 following a 1-for-50 Reverse Stock Split that took effect March 6, 2026.

What Canadian Investors Can Expect From Tevogen Inc. (NASDAQ:TVGN) on November 13, 2026

According to the screening snapshot, Tevogen Inc. publishes third-quarter 2026 results on November 13, 2026, after the market has closed, with a consensus EPS estimate of -2.5, plus a market value in the snapshot of USD 100.56 million. That estimate is a larger loss than the USD 1.52 per share posted in the second quarter, and the snapshot numbers look odd for a Business holding USD 1.08 million of cash, hence the flag. No prior-year third-quarter comparison turned up in coverage.

Latest Quarter Results and Management Outlook at Tevogen Inc. (NASDAQ:TVGN)

During second-quarter 2026, R&D spending was USD 3,282,557 and G&A spending was USD 2,379,819, putting total costs of operations at USD 5,662,376. Over six months, operating costs reached USD 11,063,296 while cash consumed by Operating Activities was USD 5,739,172. The company finished a Phase 1 proof-of-concept study of TVGN 489 in high-risk adult COVID-19 patients and plans no further clinical study before more funding arrives. Management said cash, borrowing headroom plus a grant would provide sufficient funds for a minimum of the coming 12 months.

Liquidity, Valuation and Risk Factors at Tevogen Inc. (NASDAQ:TVGN)

Total Assets stood at USD 4,727,741, on June 30, 2026, against total liabilities of USD 13,616,501 and a stockholders' deficit of USD 8,888,760. Polar notes payable of USD 1,651,000 are overdue, and the loan from a related party grew to USD 6.4 million from USD 4.4 million. The USD 1.08 million of cash equals approximately a month's worth of the cash burned in operations over six months (calculated). Shares climbed from 4,255,107 on June 30 to 6,511,540 by August 10, alongside 375,000 pre-funded warrants. Significant concerns include dilution, reliance on financing, default and listing status.

Where Things Stand

Tevogen Inc. (NASDAQ:TVGN) heads into its report with a consensus EPS estimate of -2.5 alongside a snapshot value of USD 100.56 million, far above a book position showing a USD 8,888,760 stockholders' deficit. Second-quarter costs of USD 5,662,376 and cash of USD 1.08 million mean the insider loan and any fresh Capital will matter most on the call. Clinical activity beyond the finished Phase 1 study is on hold until funding is in place. Treat the snapshot numbers with care. This note is for information only and is not a recommendation to buy or sell.